A Compendium of Clinical Research and Practice


Subscribe Current Issue Archives Continuing Education Submit an Article Contact Us
Search Articles:
Wounds Home
Current Issue
Archives
Search Articles
Subscribe to Wounds
Industry News
New Products
Classifieds
Continuing Education
Supplements
Enewsletters
Editorial Board
Contact Us
Author Instructions
Rapid Review
About Us

Bioengineered skin equivalent
Negative pressure wound therapy
Acellular dermal matrix
Diabetic neuropathy
Silver dressings
Enzymatic debridement

Autolytic debridement
Wound necrosis
Surgical debridement
Mechanical debridement
Wound fibroblasts
Delayed wound healing
Impaired wound healing
Compression stockings
Diabetic foot wounds
Pressure dressing
March 2007
Industry News:
March 2007

-


Silverlon® Negative Pressure Dressings Receives Product Innovation Award

       Argentum Medical, LLC (Willowbrook, Ill) received the 2006 Frost & Sullivan Product Innovation Award for its Silverlon® Negative Pressure Dressings.
       In more than 200 unsupported clinical cases, Silverlon dressings reduced both healing time and incidence of infection. Once placed directly on the wound surface, the filler media of choice can be placed on top of the dressing. The sustained high rate of ion release, dual flow ports for fluid management, and the durable conforming silver nylon all contribute to successful clinical results.
       Siverlon dressings reduce the required number of dressing changes, which significantly reduces patient pain and labor input.
       Visit http://www.silverlon.com for more information.

NPUAP Recognizes and Highlights Wound Care Achievements

       The National Pressure Ulcer Advisory Panel (NPUAP) honored 2 professionals with the Kosiak and Stewart awards during its biennial consensus conference.  
       Elizabeth Ayello, PhD, RN, who served as President of NPUAP in 1999, received the Koziak award. The older of the 2 NPUAP awards, it is presented to honor individuals who have made significant contributions to the prevention and/or management of pressure ulcers through their leadership in the areas of research, education, and patient care.
       Courtney Lyder, a professor with the College of Nursing with the Medical College of Virginia, received the Thomas Stewart Founder’s award. This award was created to honor individuals who have made significant contributions in the area of pressure ulcer prevention and treatment — specifically in the areas of public policy.
       Visit http://www.npuap.org or call 202-521-6789 for more information.

Winner Medical Group Signs 5-Year Wound Dressing Contract

       Winner Medical Group, Inc. (Shenzhen City, China), signed a 5-year contract with a global medical technology company to produce its nonadherent wound dressings.
       Technology driven products, such as these new nonadherent wound dressing products, mark the first order from this global medical technology products distributor. The customer plans to rebrand these products as its own and distribute them in the United States, United Kingdom, Australia, and Japan.
       Since this contract is from a leading medical technology products company the ability to develop new OEM relationships and the expansion of product accessibility is a definite. Winner Medical will be able to create and capitalize on more business opportunities in the future while mass production of the initial order is expected to commence in March 2007.
       Visit http://www.winnermedical.com for more information.

Lacosamide Provides Positive Results in aiding Diabetic Neuropathic Pain

       Schwarz Pharma (Monheim, Germany) announces that a phase III trial implementing lacosamide for the treatment of diabetic neuropathy showed statistically significant superiority compared to placebo in the primary variable.
       Patients (106) with painful diabetic neuropathy were treated in this multicenter, double blind, placebo-controlled phase III study. With such promising results underlining efficacy and safety of lacosamide in neuropathic pain, the organization is preparing the application of documents for regulatory submission.
       Schwarz Pharma has identified the novel dual mode of action for lacosamide—the selective enhancement of sodium channel slow inactivation and the modulation of CRMP-2 (collapsing response mediator protein 2). Preclinical trials showed that these novel modes of action could be the basis for the efficacy of lacosamide in the treatment of epilepsy and diabetic neuropathic pain. The mechanism might also interfere with the progression of the diseases.
       Visit http://www.schwarzpharma.com for more information.


Wounds - ISSN: 1044-7946 - Volume 19 - Issue 3 - March 2007 - Pages: A46 - A48



Supplements:

Special Publication:
The following is a collection of publications from Healthpoint intended to facilitate expeditious, cost-effective wound care management. There will be nine publications total.

Related Links:
Symposium on Advanced Wound Care (SAWC)
The Buck Stops Here
Association of Advanced Wound Care
Ostomy/Wound Management
Podiatry Today
Vascular Disease Management
Wound Healing Society

Article Submission:
All submissions for consideration should be submitted online using the Rapid Review Web-Based Review System at www.rapidreview.com. Authors should scroll down to HMP Communications and click on Author.


© 2008 HMP Communications | All Rights Reserved
83 General Warren Blvd | Suite 100 | Malvern, PA 19355